The prescription drug supply chain in the United States has long been shrouded in complexity, but a new legal firestorm in Missouri is pulling back the curtain on one of the industry’s most contentious practices. Twelve Arkansas-based independent pharmacies have launched a class-action lawsuit against Express Scripts, one of the nation’s three largest pharmacy benefit managers (PBMs), alleging a systemic, intentional pattern of underpaying pharmacies for life-saving medications in direct violation of Arkansas state law.
The lawsuit, filed in a Missouri circuit court, represents a significant escalation in the ongoing tension between independent pharmacists and the powerful PBMs that dictate the financial terms of the U.S. pharmaceutical market. At the heart of the dispute is the "National Average Drug Acquisition Cost" (NADAC)—a federal benchmark intended to ensure pharmacies are reimbursed at a rate that covers their costs. According to the plaintiffs, Express Scripts has systematically ignored this threshold, treating Arkansas law as a mere suggestion rather than a binding mandate.
The Legal Framework: Why NADAC Matters
Under Arkansas statute, PBMs are strictly prohibited from reimbursing pharmacies at rates lower than their actual cost of acquiring a drug. This cost is measured by the NADAC, a metric maintained by the federal government based on actual invoice data from pharmacies across the country.
The NADAC serves as a vital protective layer for independent pharmacies. Because these small businesses lack the massive purchasing power of large chains or the vertical integration of PBM-owned pharmacies, they operate on razor-thin margins. If a pharmacy is forced to dispense a drug for less than the cost it paid to stock it, the pharmacy effectively pays for the privilege of serving the patient.
In the complaint, the 12 plaintiff pharmacies argue that Express Scripts has full access to NADAC data, as well as specific information regarding drug costs, quantities, and fill dates. They contend that the recurring patterns of underpayment are not the result of "glitches" or isolated administrative errors, but are instead the product of a deliberate business model designed to maximize PBM profits at the expense of local providers.
"Express Scripts’ failure to comply with Arkansas law is not a technological challenge; it is a business decision," the complaint states. "Express Scripts repeatedly chose to violate Arkansas law."
A Chronology of Conflict: From Regulatory Bulletins to Civil Litigation
The current lawsuit is the culmination of years of mounting frustration and escalating regulatory intervention.
- 2021: Following a wave of reports from pharmacies regarding chronic underpayments, the Arkansas Insurance Department issued a series of bulletins. These documents sought to clarify state requirements and warned PBMs that they would be held accountable for failing to reimburse at or above the NADAC.
- 2024: After warnings failed to yield compliance, Arkansas regulators began issuing per-prescription penalties against major PBMs, including Express Scripts, marking a new phase of aggressive enforcement.
- 2024-2025: The Arkansas legislature took a historic step, passing a law that granted pharmacies the explicit authority to file civil lawsuits against PBMs for violating maximum allowable cost (MAC) and reimbursement laws. The law, which took effect in the summer of 2024, provided a potent legal weapon: statutory damages of up to $10,000 per violation.
- August 2025 – March 2026: Despite the new legal landscape, the plaintiffs allege that Express Scripts continued its practices, underpaying roughly 48,300 prescriptions during this eight-month period alone.
Supporting Data: The Cost of Underpayment
The plaintiffs acknowledge that their estimate of 48,300 underpaid prescriptions is likely conservative. Because PBMs operate with a high degree of opacity, independent pharmacies often lack full visibility into the adjudication data that would reveal the total scale of the financial shortfall.
The economic impact of these "micro-underpayments"—often amounting to just a few cents or a few dollars per prescription—is compounding. When repeated tens of thousands of times, the shortfall creates a significant liquidity crisis for independent pharmacies. The complaint highlights the human cost of these business decisions: the capital being withheld is the same cash flow needed to purchase insulin, antibiotics, anticoagulants, and seizure medications for the next patient in line.
The pharmacies are now seeking a trial to determine the full scope of the underpayments. Given that the law allows for damages of up to $10,000 per violation, the potential financial liability for Express Scripts could reach hundreds of millions of dollars, depending on the court’s interpretation of each individual claim.
The "Big Three" and the Crisis of Consolidation
To understand the significance of this lawsuit, one must examine the structure of the U.S. pharmaceutical market. PBMs function as the primary gatekeepers of the healthcare system. They negotiate drug prices with manufacturers, decide which medications are covered on insurance formularies, and determine the reimbursement rates for pharmacies.
While there are roughly 70 PBMs in the United States, the market is defined by a extreme level of concentration. Three companies—Cigna’s Express Scripts, CVS Health’s Caremark, and UnitedHealth’s Optum Rx—control approximately 80% of all prescriptions dispensed in the U.S.
This "Big Three" dominance has drawn intense scrutiny from the Federal Trade Commission (FTC). Research from the agency suggests that these conglomerates have utilized their market power to favor their own affiliated mail-order and specialty pharmacies, often leaving independent pharmacies at a structural disadvantage. By squeezing the margins of independent competitors through low reimbursement, critics argue that PBMs are effectively driving local pharmacists out of business, consolidating more market share for their own internal operations.
Official Responses and Industry Defense
PBMs have consistently denied claims of anti-competitive behavior. Industry representatives argue that they play a crucial role in managing drug costs for employers and government health plans. They maintain that their reimbursement structures are designed to be fair and that the complexities of pharmaceutical pricing are often misunderstood by the public and by state regulators.
However, the legal environment is shifting. As federal guardrails remain elusive, individual states are taking matters into their own hands. Arkansas, in particular, has positioned itself as the vanguard of the anti-PBM movement. In addition to the reimbursement laws at the heart of this lawsuit, Arkansas passed landmark legislation last year that would have forbidden PBMs from owning pharmacies within the state—a move intended to prevent conflicts of interest.
That specific law was quickly challenged by a coalition of PBMs, including Express Scripts, and was blocked by a federal judge last summer. The failure of that effort has only increased the focus on the current civil litigation as a primary tool for holding PBMs accountable.
Implications for the Future of Healthcare
The outcome of the Pharmacy vs. Express Scripts case will have profound implications for the U.S. healthcare landscape.
For Independent Pharmacies: A victory for the plaintiffs would establish a vital precedent, confirming that state laws regarding drug reimbursement have "teeth" and that PBMs cannot simply treat statutory penalties as an acceptable cost of doing business. It could empower pharmacies in other states to file similar suits, potentially triggering a nationwide legal reckoning for the PBM industry.
For Consumers: While the immediate dispute is between pharmacies and middlemen, the long-term impact on patients is significant. Independent pharmacies are often the only source of medication in rural or underserved urban areas. If these businesses are rendered financially unsustainable by PBM reimbursement policies, the result will be a decline in access to care, longer wait times for prescriptions, and the loss of the personalized clinical services that independent pharmacists provide.
For Regulatory Policy: The case highlights the ongoing friction between state-level consumer protection and the massive, cross-state influence of PBM conglomerates. If the courts rule that PBMs are bound by state-level reimbursement benchmarks, it may force the industry to overhaul its opaque pricing models. Conversely, if Express Scripts succeeds in defending its practices, it may lead to renewed calls for federal intervention and antitrust action from Congress.
As the litigation proceeds, the eyes of the pharmaceutical industry remain fixed on the Missouri courtroom. Whether this case marks the beginning of a sustained decline in PBM power or a reaffirmation of the status quo remains to be seen. What is clear, however, is that the era of "business as usual" for the pharmacy benefit management industry is facing its most significant legal challenge to date.
